Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Sep 30, 2015 5:50pm
186 Views
Post# 24151071

RE:RE:RE:RE:What's happening at the AGM

RE:RE:RE:RE:What's happening at the AGMBfw, Not so fast. I think cutthewab (princeofcut) needs a more remedial math lesson before getting into stats. He wrote "four, nice summary of the AGM i have two comments" followed by a), b), c) and then his lipitor question. 

BTW, before you (cutthewabs/princeofcut) even go off with the bearskin pumpertrash blah blah blah, let's just clear the air about my previous speculation that the BETonMACE trial might be ended early. This statement of mine was made before any of us knew that it would 1) be based on 3-point not 5-point MACE and 2) prior to yesterday's definitive comment by Don that there wouldn't be any interim analysis/sneak peaks of BETonMACE other than safety data by data safety monitoring committee. As Bfw alluded to, it is amazing that they acheived positive stats on the 5-point MACE with such small trial numbers and in only 6 months. Now that we know there is no sneak peak and we have more definitive trial design information, I can officially end my speculation. Of course, you're still going to spin this into you tiresome pumpertrash blah blah blah. But the point is more infomation has been disclosed about the trial design, eliminating the need to speculate. But I still stand by my previous analysis at the time, which is now irrelevant because of what we all know now. And of course the number of patients and amount of time to reach 250 3-point MACE events is greater than if it was a 5-point scale. Hindsight is always 20/20. Don't play the "I knew it, I was right all along" game. You knew as much as the rest of us at the time and just chose to not believe the numbers. 
 
Best,

BDAZ 
Bullboard Posts